Fig. 10
Clinical assessment of nanoformulations. (a) The images show tear meniscus height (TMH) measurement, lipid layer (TF-LL) pattern and (b) grading scale of interferometric patterns of Pre, DED, Ctrl, CsA, p(MPC), p(MPC1-co-DMA1), p(MPC3-co-DMA1), and p(MPC6-co-DMA1) groups at h12 and 4 days. The blue and red dash line represents the value of Pre and DED group, respectively. (c) The wetted length of the Schirmer paper strip for the rabbit eyes before drug administration (Pre) and those with experimentally induced DED 4 days after topical administration of CsA, p(MPC), p(MPC1-co-DMA1), p(MPC3-co-DMA1), and p(MPC6-co-DMA1). DED animals receiving artificial tear solution (ATS) without nanomaterial and drug serve as control groups (Ctrl). Values are mean ± SD (n = 6). *p < 0.05 vs. all groups; +p < 0.05 vs. Pre, DED, p(MPC), p(MPC1-co-DMA1), p(MPC3-co-DMA1), and p(MPC6-co-DMA1); #p < 0.05 vs. Pre, DED, p(MPC1-co-DMA1), p(MPC3-co-DMA1), and p(MPC6-co-DMA1); ^p < 0.05 vs. Pre, DED, Ctrl, CsA, p(MPC), and p(MPC6-co-DMA1). (d) The tear film first break-up time (NIF-BUT) and tear film average break-up time (NIAvg-BUT) measurements of Pre, DED, Ctrl, CsA, p(MPC), p(MPC1-co-DMA1), p(MPC3-co-DMA1), and p(MPC6-co-DMA1) groups at h12 and 4 days